Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 668 of 6351
-
Could radiation plus immunotherapy replace chemo before lung cancer surgery?
Disease control Recruiting nowThis randomized phase II trial is to explore the clinical efficacy, safety and feasibility of neoadjuvant immunotherapy plus radiotherapy compared with neoadjuvant immunotherapy plus chemotherapy in operable stage II-IIIA (N+) non small cell lung cancer (NSCLC) and the optimal ra…
Phase 2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug HLX43 aims to shrink Hard-to-Treat gynecologic cancers
Disease control Recruiting nowThe study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or intolerance to standard first-line therapy.
Phase 2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a few short nights of sleep tip the scales toward high blood pressure?
Knowledge-focused Recruiting nowThe purpose of this study is to research the effects of partial sleep deprivation (sleep restriction) in a group of individuals whose parents have high blood pressure compared to a group of individuals whose parents have normal blood pressure.
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a new antibiotic outperform standard care for pneumonia?
Disease control CompletedThe goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two t…
Phase 4 • Sponsor: Dr. Md. Alimur Reza • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for breast cancer patients whose tumors resisted standard therapy
Disease control OngoingEvaluation of the Efficacy and Safety of TQB3616 Capsules Combined with Hormonal Therapy in a Phase II Clinical Trial for Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor-Resistant, HR-Positive, HER2-Negative Recurrent/Metastatic Breast Cancer.
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
A sip of food dye may expose a hidden gut leak linked to ICU survival
Knowledge-focused Recruiting nowMultivisceral failure syndrome (MVFS) in humans is associated with a very high risk of mortality, ranging between 30 and 50%. This syndrome is associated with significant systemic inflammation and a high risk of bacteremia, the origin of which is not always identified. Among the …
Sponsor: Direction Centrale du Service de Santé des Armées • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
New combo treatment hope for advanced liver cancer patients
Disease control Recruiting nowThis trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the treatment of advanced hepatocellular carcinoma. Eligib…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a lower tamoxifen dose be just as good for Low-Risk breast cancer?
Disease control PausedThis phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogen…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug duo aims to halt rare cancer's growth
Disease control Recruiting nowThe purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed d…
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug cocktail aims to supercharge weight loss
Disease control CompletedThe purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or ov…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise in early colon cancer trial
Disease control Recruiting nowThe main goal of this study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a specific type of chemotherapy called CAPEOX (short for "capecitabine + oxaliplatin") to check if using these two together works better than using just…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V mutation.
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug duo takes on tough liver cancers
Disease control Recruiting nowThe goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New procedure aims to stop brain bleeds from coming back
Disease control Recruiting nowChronic Subdural Hematomas (cSHD) are common, and due to cerebral compression, often result in neurological impairment and reduced consciousness. Surgery is typically performed once neurological symptoms develop. Recent studies suggest that arteries nourished by the middle mening…
Sponsor: University Hospital, Geneva • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for kids with tough leukemia: chemo combo trial launches
Disease control Recruiting nowTo find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for CML patients with Hard-to-Treat mutation?
Disease control Recruiting nowThe objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation. The presence of this mutation introduces treatment difficulties due to the limited available options. The study seeks to collect addit…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hormone combo could boost diabetes control in menopause
Disease control OngoingThe overall aim is to investigate the hypothesis that restoring E2 levels through MHT improves glucose and energy homeostasis and potentiates the beneficial effects of GLP-1RA in early postmenopausal women with pre- or existing type 2 diabetes. The primary objective is to assess…
Sponsor: Lia Bally • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a Pre-Surgery immune booster beat standard care for skin cancer?
Disease control PausedThis phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may hav…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail aims to shrink head and neck tumors better than standard care
Disease control OngoingMaster protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New vaccine targets 21 pneumonia strains in infant trial
Vaccine OngoingThis study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 t…
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 12:07 UTC